|
|
Exchange: |
Nasdaq National Market |
Security
Type: |
Common |
Shares
Out: |
188,370,000 |
Market
Cap: |
16.70(B) |
Last
Volume: |
1,778,607 |
Avg
Vol: |
1,398,026 |
52
Week Range: |
$76.22 - $99 |
|
Level
I Sector: |
Health Care |
Level
II Sector: |
Drugs |
Level
III Sector: |
Drug Manufacturers - Other |
|
Member Indexes:
|
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
|
NASDAQ NNM COMPOSITE |
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : 811 |
Guru Rank Value : 0.9 |
Guru Occurances : 1 |
|
|
|
|
|
|
|
Company Profile BioMarin Pharmaceutical is a biotechnology company that develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Co.'s commercial products are Aldurazyme (laronidase) for Mucopolysaccharidosis I; Brineura (cerliponase alfa) for the treatment of late infantile neuronal ceroid lipofuscinosis type 2; Kuvan (sapropterin dihydrochloride) for the treatment of phenylketonuria; Naglazyme (galsulfase) the treatment of Mucopolysaccharidosis VI ; Palynziq (pegvaliase-pqpz) for adult patients with phenylketonuria; and Vimizim (elosulfase alpha) for the treatment of Mucopolysaccharidosis IV Type A.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
3,625 |
Total Buy Value |
$0 |
$0 |
$0 |
$314,469 |
Total People Bought |
0 |
0 |
0 |
1 |
Total Buy Transactions |
0 |
0 |
0 |
1 |
Total Shares Sold |
159,588 |
251,929 |
319,053 |
656,089 |
Total Sell Value |
$13,270,852 |
$21,508,551 |
$27,661,182 |
$61,420,002 |
Total People Sold |
5 |
6 |
7 |
7 |
Total Sell Transactions |
10 |
19 |
27 |
56 |
End Date |
2024-03-28 |
2023-12-26 |
2023-06-27 |
2022-06-27 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Mueller Brian |
EVP, Chief Financial Officer |
|
2022-12-02 |
4 |
AS |
$104.50 |
$731,605 |
D/D |
(7,001) |
27,746 |
|
- |
|
Mueller Brian |
EVP, Chief Financial Officer |
|
2022-12-02 |
4 |
OE |
$67.81 |
$400,079 |
D/D |
5,900 |
31,507 |
|
- |
|
Mueller Brian |
EVP, Chief Financial Officer |
|
2022-11-23 |
4 |
AS |
$95.09 |
$531,092 |
D/D |
(5,379) |
28,847 |
|
- |
|
Mueller Brian |
EVP, Chief Financial Officer |
|
2022-11-23 |
4 |
OE |
$67.81 |
$237,335 |
D/D |
3,500 |
32,347 |
|
- |
|
Bienaime Jean Jacques |
Chief Executive Officer |
|
2022-11-02 |
4 |
A |
$86.12 |
$8,612 |
D/D |
100 |
322,924 |
|
- |
|
Ajer Jeffrey Robert |
EVP, Chief Commercial Officer |
|
2022-11-02 |
4 |
AS |
$86.12 |
$258,360 |
D/D |
(3,000) |
41,088 |
|
- |
|
Alles Mark J |
Director |
|
2022-10-31 |
4 |
B |
$86.75 |
$314,469 |
D/D |
3,625 |
10,905 |
2.39 |
- |
|
Bienaime Jean Jacques |
Chief Executive Officer |
|
2022-10-31 |
4 |
S |
$86.55 |
$129,825 |
D/D |
(1,500) |
322,824 |
|
- |
|
Bienaime Jean Jacques |
Chief Executive Officer |
|
2022-10-14 |
4 |
AS |
$89.89 |
$359,560 |
D/D |
(4,000) |
324,324 |
|
- |
|
Bienaime Jean Jacques |
Chief Executive Officer |
|
2022-08-15 |
4 |
AS |
$95.21 |
$285,630 |
D/D |
(3,000) |
328,324 |
|
- |
|
Bienaime Jean Jacques |
Chief Executive Officer |
|
2022-08-12 |
4 |
AS |
$94.75 |
$379,000 |
D/D |
(4,000) |
331,324 |
|
- |
|
Ajer Jeffrey Robert |
EVP, Chief Commercial Officer |
|
2022-08-11 |
4 |
AS |
$95.62 |
$286,860 |
D/D |
(3,000) |
44,088 |
|
- |
|
Davis George Eric |
EVP, Chief Legal Officer |
|
2022-08-09 |
4 |
S |
$95.93 |
$4,914,664 |
D/D |
(51,216) |
55,251 |
|
- |
|
Davis George Eric |
EVP, Chief Legal Officer |
|
2022-08-09 |
4 |
OE |
$67.81 |
$3,222,738 |
D/D |
47,526 |
102,777 |
|
- |
|
Guyer Charles Greg |
EVP, Chief Technical Officer |
|
2022-08-08 |
4 |
S |
$96.56 |
$599,155 |
D/D |
(6,205) |
42,168 |
|
- |
|
Mueller Brian |
EVP, Chief Financial Officer |
|
2022-08-05 |
4 |
AS |
$94.50 |
$330,750 |
D/D |
(3,500) |
30,726 |
|
- |
|
Mueller Brian |
EVP, Chief Financial Officer |
|
2022-08-05 |
4 |
OE |
$67.81 |
$237,335 |
D/D |
3,500 |
34,226 |
|
- |
|
Mueller Brian |
EVP, Chief Financial Officer |
|
2022-07-08 |
4 |
AS |
$89.50 |
$656,662 |
D/D |
(7,337) |
30,726 |
|
- |
|
Davis George Eric |
EVP, Chief Legal Officer |
|
2022-07-08 |
4 |
AS |
$90.00 |
$665,820 |
D/D |
(7,398) |
58,941 |
|
- |
|
Mueller Brian |
EVP, Chief Financial Officer |
|
2022-06-29 |
4 |
D |
$83.92 |
$48,338 |
D/D |
(576) |
38,063 |
|
- |
|
Ajer Jeffrey Robert |
EVP, Chief Commercial Officer |
|
2022-06-03 |
4 |
D |
$77.49 |
$544,057 |
D/D |
(7,021) |
47,088 |
|
- |
|
Ajer Jeffrey Robert |
EVP, Chief Commercial Officer |
|
2022-05-26 |
4 |
AS |
$78.94 |
$103,254 |
D/D |
(1,308) |
54,109 |
|
- |
|
Alles Mark J |
Director |
|
2022-05-24 |
4 |
A |
$0.00 |
$0 |
D/D |
4,980 |
7,280 |
|
- |
|
Slamon Dennis |
Director |
|
2022-05-24 |
4 |
A |
$0.00 |
$0 |
D/D |
4,980 |
26,619 |
|
- |
|
Ho Maykin |
Director |
|
2022-05-24 |
4 |
A |
$0.00 |
$0 |
D/D |
4,980 |
12,450 |
|
- |
|
1285 Records found
|
|
Page 8 of 52 |
|
|